Table 1

Proportion of cells in each sample displaying significant signal amplifications or deletions of each fluorescence in situ hybridisation probe utilised

PatientPathology% 4L% 4G% 8L% 8G% 9L% 9G% p16L% p16G% RbL% RbG% p53L% p53G% 20L% 20G% YL
G, signal gains; L, signal losses; F, female patients.
BM, metaplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; OA, oesophageal adenocarcinoma.
All blank cells indicate samples that were normal (that is, did not display signal losses/gains above the cut off limits).
2BM 3.3 3.5 3.7
3BM 7.1 1.8 3.2 4.9
4BM22.8 1.3
5BM61.3 7.1 6.4
8BM4.5 1.0 2.8 1.5
11BM
16BM 4.7 2.8
19BM 8.5 1.3 F
20BM 5.6 4.5 3.8
33BM13.5 4.7 F
35BM 9.7 F
46BM 7.8 F
49BM 9.0
51BM 1.8 7.0
63BM14.5 4.219.8
73BM 2.8 1.3 F
86BM25.3 3.8
95BM13.9 2.3 F
100BM37.3
105BM 5.5 7.8
107BM 3.3 5.5
109BM 3.3 2.5 F
111BM 4.5 3.8 F
117BM 5.8 6.8 F
121BM19.8 25.352.333.3
127BM 4.3 3.326.8
131BM 8.8 3.512.5
135BM 9.316.8 1.0
9LGD55.9 5.4 3.7 1.4
18LGD 5.438.7
21LGD12.5 3.42.2 6.6 8.1
27LGD14.3
29LGD29.092.8 F
31LGD2.8
36LGD 2.4 4.515.8 7.3
40LGD28.5
53LGD 8.5 3.7 1.5 F
55LGD 1.54.3 4.8 4.8
57LGD 1.8 2.32.0 1.310.5
65LGD 2.5 2.3 2.75 6
69LGD 5.310.4 4.517.25
80LGD 6.2 1.8 5.0
89LGD47.3 8.02.0 9.8 6.3
98LGD 2.0 3.2 5.0
123LGD 8.0 3.3
129LGD 6.3 6.5 F
133LGD 7.8 6.5
141LGD 4.5 8.1 2.7 F
1HGD4.7 1.7 6.5 111.3
10HGD25.420.818.734.92.011.5 9.366.8
12HGD 9.6 1.321.5 8.5 7.8
25HGD26.7 1.545.36.310.3
42HGD10.22.8 2.5 5.8 5.5
91HGD50.620.011.0 5.512 F
102HGD25.548.038.036.011.4
139HGD 9.518.5 8.89.5 5.810.2
15OA32.42.7 3.01.5 4.3 5.8 7.7 4.2 F
17OA16.563.8 1.3 5.01.05.1 2.22.2 1.363.3
22OA54.012.02.2 8.510.04.63.0 2.3 7.81.415.810.3
48OA86.05.511.02.3 5.811.84.015.810.89.016.5 F
83OA65.8 5.37.028.0 8.04.043.3
88OA13.311.56.0 6.036.0 5.31.0 7
97OA11.0 8.56.8 2.314.31.3 4.0 6.01.0 7